Evidence map›Paper›PMID 42655201›Full record

ArticleMicroorganisms2026

Combined Plasmid Redesign and Transfection Optimization Significantly Increases Upstream AAV Titers While Maintaining Vector Quality and In Vivo Potency.

Shiliang Hu, Yinxing Chen, Carmen Wu, Wilhad Hans Reuter, June Deng, Nannan Jia, Noel Walsh, Amy Bastille, Thomas M Edwards, Matthias Hebben and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Microorganisms, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Shiliang HuGenomic Medicine, Alexion, AstraZeneca Rare Disease, 100 Binney Street, Cambridge, MA 02142, USA.
Yinxing ChenGenomic Medicine, Alexion, AstraZeneca Rare Disease, 100 Binney Street, Cambridge, MA 02142, USA.
Carmen WuLogicBio Therapeutics, 65 Hayden Avenue, Lexington, MA 02421, USA.
Wilhad Hans ReuterLogicBio Therapeutics, 65 Hayden Avenue, Lexington, MA 02421, USA.
June DengGenomic Medicine, Alexion, AstraZeneca Rare Disease, 100 Binney Street, Cambridge, MA 02142, USA.
Nannan JiaGenomic Medicine, Alexion, AstraZeneca Rare Disease, 100 Binney Street, Cambridge, MA 02142, USA.
Noel WalshGenomic Medicine, Alexion, AstraZeneca Rare Disease, 100 Binney Street, Cambridge, MA 02142, USA.
Amy BastilleGenomic Medicine, Alexion, AstraZeneca Rare Disease, 100 Binney Street, Cambridge, MA 02142, USA.
Thomas M EdwardsLogicBio Therapeutics, 65 Hayden Avenue, Lexington, MA 02421, USA.
Matthias HebbenLogicBio Therapeutics, 65 Hayden Avenue, Lexington, MA 02421, USA.ORCID 0000-0002-2684-1153
Nelson ChauGenomic Medicine, Alexion, AstraZeneca Rare Disease, 100 Binney Street, Cambridge, MA 02142, USA.
Jing LiaoGenomic Medicine, Alexion, AstraZeneca Rare Disease, 100 Binney Street, Cambridge, MA 02142, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A high manufacturing cost of goods (CoG) remains a critical barrier to the broad clinical adoption of gene therapies and is driven in part by limited productivity in adeno-associated virus (AAV) manufacturing. Here, we report an optimized AAV production process developed to markedly increase upstream titers while preserving vector quality and potency. The process combines a redesigned plasmid system, an optimized plasmid ratio, and a novel synthetic transfection reagent and was benchmarked against a conventional triple-plasmid/PEI MAX workflow. Across multiple AAV capsids and independent production runs, the optimized process reproducibly increased crude harvest titers by approximately 10- to 33-fold relative to the standard process, while maintaining key vector quality attributes. Notably, within the detection limits of the assay, rcAAV was undetectable at 1 × 10

Indexed as

AAV production processreplication-competent AAV (rcAAV)two-plasmid system (2P)

Identifiers

PMID42655201
PMCPMC13515234

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.